CN102600374B - Medicine for preventing parkinsonism and application of medicine - Google Patents
Medicine for preventing parkinsonism and application of medicine Download PDFInfo
- Publication number
- CN102600374B CN102600374B CN201210063022.3A CN201210063022A CN102600374B CN 102600374 B CN102600374 B CN 102600374B CN 201210063022 A CN201210063022 A CN 201210063022A CN 102600374 B CN102600374 B CN 102600374B
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- trannum
- chinese medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine and application in terms of preparation of the medicine for preventing parkinsonism. The medicine is prepared by following bulk drug including, by weight, from 5 to 10 parts of gastrodia elata, from 5 to 10 parts of astragalus mongholicus, from 5 to 10 parts of prepared rehmannia roots, from 5 to 15 parts of radix paeoniae alba, from 5 to 10 parts of Chinese angelica, from 5 to 10 parts of uncaria, from 2 to 10 parts of bombyx batryticatus and from 2 to 10 parts of rhizoma arisaematis. The traditional Chinese medicine and the application thereof have the advantages that compatibility of the traditional Chinese medicine meets a traditional Chinese medicine 'assistant and guide' principle, medicine types are fewer, the traditional Chinese medicine is high in curative effect, free of toxic and side effects, cheap in price and the like, adopts rules including a rule of tonifying qi to promote blood circulation, a rule of nourishing yin for suppressing hyperactive yang, a rule of calming liver to stop endogenous wind, a rule of massaging muscles to stop endogenous wind, a rule of promoting blood circulation to remove blood stasis, a rule of dredging collaterals to stop endogenous wind and the like, aims to prevent pathogenic foundation, suits the remedy to the case so as to realize a prevention effect, is simple in preparation method and low in cost, is environment-friendly, is suitable for being orally taken for a long time, is a traditional Chinese medicine composition which safely and effectively prevents the parkinsonism and parkinsonism motion complications, and has a fine application prospect.
Description
Technical field
The present invention relates to a kind of Chinese medicine, specifically, is the Parkinsonian Chinese medicine composition of a kind of prevention and application thereof.
Background technology
Parkinson disease (Parkinson ' s disease, PD) be the common nervous system degeneration illness of middle-aged and elderly people, the nigrostriatum path dopamine mediator that mainly lacks and cause thus with black substance dense area degeneration of dopaminergic neurons reduces relevant.Through clinical practice for many years, it is generally acknowledged, levodopa is still the most effective medicine.But after prolonged application, most of patient there will be symptom fluctuation, the dyskinesia and mental symptom.In addition laboratory finds that high concentration dopamine (dopamine, DA) and levodopa, because autoxidation produces free radical, can cause neurocyte degeneration necrosis.Therefore, associating other drug jointly prevent PD and PD motor complication very urgent.
In addition, research finds that striatum GRKs and the variation of Arrestins expression and the development of PD are in close relations.Research in recent years shows, the signal transduction pathways such as the direct path of the generation of parkinson disease motor complication and expression D1 receptor and downstream cAMP deopendent protein kinase (PKA), ERK are activated in close relations, phosphorylated protein-32 (the dopamine and cAMP-regulated phosphoprotein of Mr 32000 that its downstream signal transducin dopamine and adenosine cyclophosphate regulate, the change of albumen Thr75 site Expression of phosphorylated DARPP-32) may participate in the morbidity of unusual fluctuation disease (1evodopa-induced dyskinesia, LID).
Think at present and use levodopa controlled release agent, dopamine-receptor stimulant, monoamine oxidase B (monoamine oxidase-B type, MAO-B) appearance that inhibitor and catechol-oxygen position-methyltransferase inhibitors (eateehol-O-methyl transferase inhibitor, COMTI) can delayed motion complication.But these medicines often side effect are larger, easily form drug resistance, unsuitable long-term taking.China is accumulating rich experiences aspect Chinese medicine prevention PD, and summing up its Precautionary Principle is benefiting QI for activating blood circulation method, nourishing YIN for attracting YANG method, and suppressing the hyperactive liver to relieve the wind syndrome method, rubs the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., activating blood and removing stasis Method and the dredging collateral rule such as relieve dizziness, high fever, infantile convulsions, epilepsy, etc.
Chinese patent literature CN100409867C discloses a kind of capsule that only quivers that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., and the herbal mixture being comprised of the Radix Paeoniae Alba, Ramulus Uncariae Cum Uncis etc. is provided, and prevention PD, improves tremble symptom, myotonia, akinesia shape.Li Min etc. have proposed Kidney-Invigorating & Blood-Activating Herbs can improve PD patient moving complication symptom, and curative effect increases with prevention time lengthening, this Kidney-Invigorating & Blood-Activating Herbs is by Fructus Corni 10g, Radix Polygoni Multiflori 15g, Radix Salviae Miltiorrhizae 15g, the Chinese medicine such as Hirudo 6g forms, but not disclose other Chinese medicine ingredients (refer to: Li Min etc. invigorating kidney, promoting blood circulation granule prevents the clinical research of parkinson disease motor complication. Chinese Chinese medicine magazine, 2011,26 (6): 1296-1299.).But yet there are no report about the Parkinsonian Chinese medicine composition of a kind of prevention and application thereof.
Summary of the invention
The object of the invention is for deficiency of the prior art, the application of a kind of Chinese medicine in the Parkinsonian disease medicament of preparation prevention is provided.
One object more of the present invention is to provide a kind of prevention Parkinsonian Chinese medicine.
For achieving the above object, the technical scheme that the present invention takes is: the application of a kind of Chinese medicine in the Parkinsonian disease medicament of preparation prevention, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 5-10 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part, Rhizoma Arisaematis 2-10 part.
Described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 6-8 part, Radix Astragali 6-8 part, Radix Rehmanniae Preparata 6-8 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-8 part, Ramulus Uncariae Cum Uncis 6-8 part, Bombyx Batryticatus 4-6 part, Rhizoma Arisaematis 4-6 part.
Described medicine is made by the crude drug of following weight portion: 8 parts, Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, 5 parts of Rhizoma Arisaematiss.
The application of described medicine in the disease medicament of preparation prevention parkinson disease motor complication.
For realizing above-mentioned second object, the technical scheme that the present invention takes is: the Parkinsonian Chinese medicine of a kind of prevention, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 5-10 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part, Rhizoma Arisaematis 2-10 part.
Described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 6-8 part, Radix Astragali 6-8 part, Radix Rehmanniae Preparata 6-8 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-8 part, Ramulus Uncariae Cum Uncis 6-8 part, Bombyx Batryticatus 4-6 part, Rhizoma Arisaematis 4-6 part.
Described medicine is made by the crude drug of following weight portion: 8 parts, Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, 5 parts of Rhizoma Arisaematiss.
The application of described medicine in the disease medicament of preparation prevention parkinson disease motor complication.
The dosage form of described medicine is tablet, capsule, granule, mixture, oral liquid or syrup.
The invention has the advantages that:
1, Chinese medicine composition of the present invention, its compatibility meets Chinese medicine " monarch " principle, and flavour of a drug number is less, have curative effect high, have no side effect, the advantage such as price is low, adopt benefiting QI for activating blood circulation method, nourishing YIN for attracting YANG method, suppressing the hyperactive liver to relieve the wind syndrome method, rubs the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., the rules such as activating blood and removing stasis Method and dredging collateral relieve dizziness, high fever, infantile convulsions, epilepsy, etc., from cause of disease, start with at all, suit the remedy to the case, to reach preventive effect;
2, preparation method is simple, and cost is low, environmentally friendly, is suitable for long-term taking, is a kind of Chinese medicine composition that prevents safely and effectively parkinson disease and parkinson disease motor complication, has a good application prospect.
Accompanying drawing explanation
Accompanying drawing 1 is the impact of various dose group Chinese medicine on PD rat model AIM total points, # small dose group and the comparison of Western medicine group, all P < 0.05; * middle dosage group and small dose group comparison, all P < 0.05; + heavy dose of group and the comparison of middle dosage group, all P < 0.05.
Accompanying drawing 2 is the impacts on PD rat model agent peak number of revolutions of various dose Chinese medicine composition, # Western medicine group and small dose group comparison, all P < 0.05; * middle dosage group and small dose group comparison, all P < 0.01; + heavy dose of group and the comparison of middle dosage group, all P < 0.05.
Accompanying drawing 4 is Chinese medicine composition various dose Western results on the impact of PD rat model Striatum GRK6, and 1,2 is sham operated rats, and 3,4 is PD matched group, 5,6 is Western medicine group, 7,8 is TCM-small dose group, and 9,10 is dosage group in TCM-, and 11,12 is the heavy dose of group of TCM-; 1,3,5,7,9,11 for not damaging side, and 2,4,6,8,10,12 is damage side; * with sham operated rats comparison, p < 0.01; # and the comparison of PD matched group, p < 0.05; + TCM and the comparison of Western medicine group, p < 0.01.
Accompanying drawing 5 is Chinese medicine various dose ImmunohistochemistryResults Results on the impact of PD motor complication rat model Striatum β-arrestin1, and 1 is sham operated rats, and 2 is PD matched group, 3 is Western medicine group, 4 is TCM-small dose group, and 5 is dosage group in TCM-, and 6 is the heavy dose of group of TCM-; U is for not damaging side, and L is damage side.
Accompanying drawing 6 is Chinese medicine various dose Western results on the impact of PD motor complication rat model Striatum β-arrestin1,1,2 is sham operated rats, 3,4 is PD matched group, 5,6 is Western medicine group, 7,8 is TCM-small dose group, 9,10 is dosage group in TCM-, and 11,12 is the heavy dose of group of TCM-; 1,3,5,7,9,11 for not damaging side, and 2,4,6,8,10,12 is damage side.
Accompanying drawing 7 is that Chinese medicine various dose is on PD motor complication rat model Striatum phosphorylation DARPP-32(Thr75) ImmunohistochemistryResults Results of the impact expressed, A sham operated rats, B is PD matched group, C is Western medicine group, D is TCM-small dose group, and E is dosage group in TCM-, and F is the heavy dose of group of TCM-.
Accompanying drawing 8 is that Chinese medicine various dose is on PD motor complication rat model Striatum phosphorylation DARPP-32(Thr75) the Western result of the impact expressed, 1 is sham operated rats, 2 is LID matched group, 3 is Western medicine group, 4 is TCM-small dose group, 5 is dosage group in TCM-, and 6 is the heavy dose of group of TCM-.
Accompanying drawing 9 is Chinese medicine various dose ImmunohistochemistryResults Results on the impact of PD motor complication rat model Striatum phosphorylation ERK1/2 expression, A sham operated rats, and B is PD matched group, C is Western medicine group, D is TCM-small dose group, and E is dosage group in TCM-, and F is the heavy dose of group of TCM-.
Accompanying drawing 10 is Chinese medicine various dose Western results on the impact of PD motor complication rat model Striatum phosphorylation ERK1/2 expression, and 1 is sham operated rats, and 2 is PD matched group, and 3 is TCM-small dose group, and 4 is dosage group in TCM-, and 5 is the heavy dose of group of TCM-.
The specific embodiment
Below in conjunction with accompanying drawing, the specific embodiment provided by the invention is elaborated.
The invention provides the Parkinsonian Chinese medicine of a kind of prevention, described Chinese medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 5-10 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part, Rhizoma Arisaematis 2-10 part.The application of described Chinese medicine in the Parkinsonian disease medicament of preparation prevention.
the preparation (one) of embodiment 1 Chinese medicine composition
5 parts, Rhizoma Gastrodiae, 10 parts of the Radixs Astragali, 5 parts of Radix Rehmanniae Preparata, 15 parts of Radix Paeoniae Alba, 5 parts of Radix Angelicae Sinensis, 10 parts of Ramulus Uncariae Cum Uncis, 2 parts of Bombyx Batryticatus, 10 parts of Rhizoma Arisaematiss, conventional method decocts.
the preparation (two) of embodiment 2 Chinese medicine compositions
6 parts, Rhizoma Gastrodiae, 9 parts of the Radixs Astragali, 6 parts of Radix Rehmanniae Preparata, 6 parts of Radix Paeoniae Alba, 6 parts of Radix Angelicae Sinensis, 9 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus, 8 parts of Rhizoma Arisaematiss, conventional method decocts.
the preparation (three) of embodiment 3 Chinese medicine compositions
7 parts, Rhizoma Gastrodiae, 7 parts of the Radixs Astragali, 7 parts of Radix Rehmanniae Preparata, 12 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 7 parts of Ramulus Uncariae Cum Uncis, 4 parts of Bombyx Batryticatus, 4 parts of Rhizoma Arisaematiss, conventional method decocts.
the preparation (four) of embodiment 4 Chinese medicine compositions
8 parts, Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, 5 parts of Rhizoma Arisaematiss, conventional method decocts.
the preparation (five) of embodiment 5 Chinese medicine compositions
9 parts, Rhizoma Gastrodiae, 6 parts of the Radixs Astragali, 9 parts of Radix Rehmanniae Preparata, 8 parts of Radix Paeoniae Alba, 9 parts of Radix Angelicae Sinensis, 6 parts of Ramulus Uncariae Cum Uncis, 8 parts of Bombyx Batryticatus, 6 parts of Rhizoma Arisaematiss, conventional method decocts.
the preparation (six) of embodiment 6 Chinese medicine compositions
10 parts, Rhizoma Gastrodiae, 5 parts of the Radixs Astragali, 10 parts of Radix Rehmanniae Preparata, 5 parts of Radix Paeoniae Alba, 10 parts of Radix Angelicae Sinensis, 5 parts of Ramulus Uncariae Cum Uncis, 10 parts of Bombyx Batryticatus, 2 parts of Rhizoma Arisaematiss, conventional method decocts.
It should be noted that, it is the manufacture method of Chinese medicine decoction routine that the conventional method described in embodiment 1-6 decocts, and is about to described crude drug and decocts with water into decoction.
the preparation of embodiment 7 Chinese medicine composition tablets/capsules agent
Get the arbitrary described Chinese medicine composition of embodiment 1-6, add 6-10 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 6-10 times of water gaging, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 and doubly measure ethanol, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated.
the preparation of embodiment 8 Chinese medicine composition granules
Get the arbitrary described Chinese medicine composition of embodiment 1-6, add 6-10 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 6-10 times of water gaging, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 and doubly measure ethanol, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains granule, packing.
the preparation of embodiment 9 Chinese medicine composition mixture/oral liquid/syrups
Get the arbitrary described Chinese medicine composition of embodiment 1-6, add 6-10 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 6-10 times of water gaging, decoct 0.5-2 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add concentrated solution 2-3 and doubly measure ethanol, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add suitable pharmaceutical aids, make mixture, oral liquid or syrup.
the preclinical test of embodiment 10 Chinese medicine compositions of the present invention
one, experimental technique
the preparation of 1.PD rat model:according to methods such as Ba Maowen, prepare PD rat model.Get 65 rats and enter experiment, wherein 5 is sham operated rats, in medial forebrain bundle (MFB) injecting normal saline.Lumbar injection 3% pentobarbital sodium anesthetized rat, strict tack cranium position fixedly rat in stereo brain orienting instrument, with reference to bag new people, show rat brain stereotaxic atlas, determine right side medial forebrain bundle (right medical forebrain, MFB) coordinate: 1. 3.7 mm after bregma, sagittal suture right side 1.7 mm, 7.8 mm under cranial periosteum, front tooth line 2.4 mm; 2. 4.4 mm after bregma, sagittal suture right side 1.2 mm, 7.8 mm under cranial periosteum, front tooth line 2.4 mm.By the boring of above-mentioned definite injection site, with the microsyringe of 10 μ l, extract 6-OHDA6 μ l (containing 0.2% ascorbic normal saline configuration, concentration 4 μ g/ μ l), every some injection 3 μ l, the withdraw of the needle after let the acupuncture needle remain at a certain point 10 min, stitching wound surface.After 3 weeks, rats by intraperitoneal injection apomorphine (0.5 mg/kg), average speed > 7 times/min is successful PD model.
model preparation is measured with behavioristics:25 successful PD models are divided into 3 large groups at random.(1) PD matched group: PD rat model lumbar injection 0.2% vitamin C liquid 29 days; (2) Western medicine processed group: lumbar injection LDME+benserazide (50 mg/kg LDME and 25 mg/ kg benserazides, be dissolved in containing in 0.2% ascorbic sterilization normal saline), 2 times/d at (in the morning and afternoons 5 point), continue 29d at 9; (3) dosage group in Chinese medicine composition small dose group (TCM-small dose group), Chinese medicine composition (the heavy dose of group of TCM-), the heavy dose of group of Chinese medicine composition (the heavy dose of group of TCM-): give to add respectively and use Chinese medicine composition of the present invention on the basis of LDME/benserazide, 9 ml/kg, every day 1 gavage, continuous 4 weeks.In Chinese medicine composition, dosage group is prepared Chinese medicine composition with reference to the method described in embodiment 4; The heavy dose of group of Chinese medicine composition respectively increases by 20% according to each raw material of Chinese medicine medicine of middle dosage group; Chinese medicine composition small dose group respectively reduces 20% according to each raw material of Chinese medicine medicine of middle dosage group.In therapeutic process, after medication in the morning in the 2nd, 8,15,22,29 days, carry out rat behavior and learn observation and scoring.AIM evaluation: AIM is divided into 4 components (upper limb AIM, the AIM of actinal surface portion, axle AIM and rotation AIM) to be evaluated, and every part has or not with the order of severity and is divided into 5 grades (0-4) according to it again: 0 nothing; 1 persistent period was less than 30s; 2 persistent period were greater than 30s, were less than 60s; 3 persistent period were greater than 60s, and environmental stimuli can make it to stop; 4 persistent period were greater than 60s, and environmental stimuli can not make it to stop.After medication, every 20min assessment once, is observed 1min at every turn.AIM total points is added up by the meansigma methods of total mark in observing time, and after 1 rat a drug, each component AIM maximum scores is 4 minutes in theory, and total AIM scoring is 16 minutes.Agent peak number of revolutions: after injection levodopa, every 5min records number of revolutions, and maximum numbers of revolutions is agent peak number of revolutions.
sABC shows the variation of striatum β-arrestin1, GRK6, DARPP-32 (Thr75) and ERK1/2:finish 12h after injection, 3% pentobarbital sodium anesthesia, left ventricle is poured into 4% paraformaldehyde and is fixed, broken end fixing 8h after getting after brain in identical fixative, through repairing, piece, gradient alcohol dehydration, dimethylbenzene are transparent, use paraffin embedding after waxdip.Row paraffin section, slice thickness is 5 μ m.Paraffin section de-waxing is to water; 3% hydrogen peroxide room temperature lucifuge is hatched 5min, to eliminate endogenous catalase activity; 1nmol/l ethylenediaminetetraacetic acid-Tris-hydrogen chloride of PH7.7 (repair by EDTA-Tris-HCl microwave heating; 1% bovine serum albumin room temperature envelope 20min; Overnight incubation in the anti-Mus GRK6 of rabbit antibody, the anti-Mus β-arrestin1 of rabbit polyclonal antibody, the anti-Mus DARPP-32 of rabbit antibody, 4 ℃ of wet boxes of anti-phosphorylation DARPP-32 (Thr75) the antibody ,Tu Chinese People's Anti-Japanese Military and Political College Mus total ERKl/2 He Tu Mus phosphorylation ERKl/2 of Chinese People's Anti-Japanese Military and Political College monoclonal antibody; The biotin labeling two that drips dilution is anti-, hatches 20min for 37 ℃; Drip the horseradish peroxidase-labeled strepto-avidin of dilution, hatch 20min for 37 ℃; Benzidine (3,3 ˊ-diaminobenzidine tetrahydrochloride, DAB) chromogenic reagent, tap water rinses, afterwards dehydration, transparent, mounting.Between each step, all use the abundant rinsing of 0.01mol/l TBS, TBS replaces primary antibodie as negative control.Examine under a microscope SABC section, each observation area is got 5 not overlapped views at random, in high power lens (10 * 40) is lower, observe, adopt OLYMPUS-IX50 to become phase system to take, Image-Pro Plus 5.1 imgae processing softwares carry out semi-quantitative analysis, calculate positive cell index (IOD)=Positive area * correction optical density value (measurement zone optical density-background indensity).
method detects the expression of β-arrestin1, GRK6, DARPP-32 (Thr75) and ERK1/2:3h after last injection, 3% pentobarbital sodium anesthesia, broken end is got brain rapidly, peels off bilateral striatum on ice, and ultrasonic degradation extracts total protein.Measure after protein concentration, put-80 ℃ frozen standby.40 μ g egg door samples, through 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation, are transferred on polyvinylidene fluoride (PVDF) film with electric transferring film instrument.Confining liquid (5% defatted milk powder) room temperature sealing 2h, according to respective concentration, dilute anti-GRK6 antibody (1: 500), anti-β-arrestin1 antibody (1:500), anti-total DARPP-32 antibody (1:1000) or anti-phosphorylation DARPP-32 (Thr75) antibody (1:1000), anti-total ERKl/2 antibody (1:1000) or anti-phosphorylation ERKl/2 antibody (1:500) or anti-β-actin (l:1000), 4 ℃ of jog overnight incubation.Add next day two to resist, under room temperature, shaking table is hatched 1 h; Drip ECL colour developing mixed liquor, the exposure of Bio-Rad gel imaging instrument, video picture.Western blot image adopts SmartView2000 image analysis software to calculate the product of each sample destination protein band OD value and area value, thereby it is quantitative to carry out protein band density.
statistical analysis technique
Experimental data adopts SPSS 13.0 statistical softwares to analyze.Gained measurement data with mean ± standard deviation (<img TranNum="149" file="2012100630223100002DEST_PATH_IMAGE001.GIF" he="24" img-content="drawing" img-format="GIF" inline="no" orientation="portrait" wi="14"/>± s) represent that the relatively employing one factor analysis of variance of a plurality of sample averages relatively adopts t check between two.Take P < 0.05 has statistical significance as difference.
two, result
1. the impact of Chinese medicine composition on the behavior of PD rat model
the impact of 1.1 Chinese medicine compositions on each component of PD rat model AIM scoring
With regard to the AIM of actinal surface portion scoring, between the 2nd day each group, average is without significant difference.8th, average significant difference between 15,22,29 days each groups (<i TranNum="157">f</i>=4.98,<i TranNum="158">f</i>=22.70,<i TranNum="159">f</i>=30.96,<i TranNum="160">f</i>=23.27,<i TranNum="161">p</i><0.01).Wherein small dose group reduces compared with Western medicine processed group the AIM of actinal surface portion scoring in the 22nd day, and difference has statistical significance (t=2.50, P<0.05), all the other several days equal not statistically significants of difference; The 8th, 15,22,29 days AIM of actinal surface portion of middle dosage group scoring smaller dose group obviously reduces, difference have statistical significance (t=2.86, t=3.80, t=4.38, t=6.54, all<i TranNum="162">p</i><0.05); Middle dosage group and heavy dose of group relatively, only in the 22nd day heavy dose of group in the dosage group actinal surface AIM of portion scoring reduction, difference have statistical significance (<i TranNum="163">t</i>=2.50,<i TranNum="164">p</i><0.05).
With regard to upper limb AIM scoring, the 2nd, 8 days each class mean no significant differences, between the 15th, 22,29 days each groups average difference have statistical significance (<i TranNum="166">f</i>=15.12,<i TranNum="167">f</i>=32.86,<i TranNum="168">f</i>=35.80,<i TranNum="169">p</i><0.01).Medication the 2nd day and small dose group upper limb AIM scoring in the 8th day and Western medicine processed group be there was no significant difference relatively, to medication small dose group upper limb AIM scoring in the 15th, 22,29 days lower than Western medicine group, difference have statistical significance (<i TranNum="170">t</i>=4.45,<i TranNum="171">t</i>=4.47, all<i TranNum="172">p</i><0.01).15th, in 22,29 days, dosage group obviously reduces than small dose group upper limb AIM scoring, difference have statistical significance (<i TranNum="173">t</i>=3.40,<i TranNum="174">t</i>=4.04,<i TranNum="175">t</i>=3.95, all<i TranNum="176">p</i><0.01).Between heavy dose of group and middle dosage group, compare difference no difference of science of statistics.
With regard to axial AIM scoring, between the 15th, 22,29 days each groups average difference have statistical significance (<i TranNum="178">f</i>=3.30,<i TranNum="179">f</i>=25.06,<i TranNum="180">f</i>=36.41,<i TranNum="181">p</i><0.01).22,29 days axial AIM values of small dose group medication to the reduce than Western medicine processed group, difference have statistical significance (<i TranNum="182">t</i>=3.93,<i TranNum="183">t</i>=3.04, all<i TranNum="184">p</i><0.05); Middle dosage group is than small dose group comparison, only in the 29th day difference have statistical significance (<i TranNum="185">t</i>=3.05,<i TranNum="186">p</i><0.05); Heavy dose of group has obviously reduced axial AIM value, but with the comparison of middle dosage group, only variant in the 29th day (<i TranNum="187">t</i>=2.83,<i TranNum="188">p</i><0.05), put At All Other Times difference no difference of science of statistics.
With regard to rotation AIM scoring, average significant difference between the 8th, 15,22,29 days each groups (<i TranNum="190">f</i>=10.50,<i TranNum="191">f</i>=11.62,<i TranNum="192">f</i>=18.92,<i TranNum="193">f</i>=61.26,<i TranNum="194">p</i><0.01).Small dose group and Western medicine processed group rotation AIM scoring are compared, difference not statistically significant.Middle dosage group medication to the 15,22,29 days, rotation AIM scoring obviously reduces than Western medicine group, difference have statistical significance (<i TranNum="195">t</i>=3.43,<i TranNum="196">t</i>=5.11,<i TranNum="197">t</i>=7.63, all<i TranNum="198">p</i><0.01); Heavy dose of group and the comparison of middle dosage group, the 8th, 15,29 days obvious differences (<i TranNum="199">t</i>=3.81,<i TranNum="200">t</i>=2.52,<i TranNum="201">t</i>=3.58, all<i TranNum="202">p</i><0.05).
the comparison of table 1 Chinese drug-treated group and Western medicine group AIM scoring (
± S, minute)
| Time | Group | Mus number (only) | Actinal surface portion | Upper | Axially | Rotation | |
| 2d | The heavy dose of group of TCM- | 5 | 1.42±0.24 | 1.62±0.26 | 2.38±0.15 | 2.62±0.23 | |
| ? | Dosage group in TCM- | 5 | 1.40±0.19 | 1.56±0.28 | 2.51±0.22 | 2.71±0.34 | |
| ? | TCM- |
5 | 1.51±0.17 | 1.58±0.19 | 2.42±0.16 | 2.62±0.23 | |
| ? | Western medicine processed |
5 | 1.44±0.18 | 1.51±0.22 | 2.49±0.17 | 2.67±0.28 | |
| 8d | The heavy dose of group of TCM- | 5 | 1.51±0.22 | 1.67±0.22 | 2.42±0.24 | 2.60±0.06 | |
| ? | Dosage group in TCM- | 5 | 1.56±0.18 | 1.76±0.16 | 2.58±0.29 | 2.93±0.19 | |
| ? | TCM- |
5 | 1.89±0.21 | 1.91±0.19 | 2.76±0.41 | 3.16±0.20 | |
| ? | Western medicine processed |
5 | 1.82±0.17 | 1.93±0.20 | 2.71±0.41 | 3.20±0.25 | |
| 15d | The heavy dose of group of TCM- | 5 | 1.33±0.11 | 1.51±0.22 | 2.38±0.20 | 2.58±0.15 | |
| ? | Dosage group in TCM- | 5 | 1.47±0.14 | 1.71±0.22 | 2.69±0.24 | 2.84±0.19 | |
| ? | TCM- |
5 | 1.84±0.17 | 2.09±0.12 | 2.71±0.37 | 3.09±0.24 | |
| ? | Western medicine processed |
5 | 2.11±0.22 | 2.18±0.15 | 2.93±0.28 | 3.36±0.28 | |
| 22d | The heavy dose of group of TCM- | 5 | 1.29±0.13 | 1.49±0.23 | 2.24±0.18 | 2.53±0.15 | |
| ? | Dosage group in TCM- | 5 | 1.49±0.13 | 1.69±0.20 | 2.29±0.13 | 2.67±0.11 | |
| ? | TCM- |
5 | 1.96±0.20 | 2.13±0.14 | 2.62±0.28 | 3.11±0.21 | |
| ? | Western medicine processed |
5 | 2.40±0.37 | 2.56±0.16 | 3.18±0.15 | 3.38±0.29 | |
| 29d | The heavy dose of group of TCM- | 5 | 1.20±0.09 | 1.53±0.21 | 2.11±0.78 | 2.29±0.10 | |
| ? | Dosage group in TCM- | 5 | 1.33±0.21 | 1.67±0.18 | 2.33±0.16 | 2.56±0.14 | |
| ? | TCM- |
5 | 2.04±0.13 | 2.13±0.20 | 2.76±0.26 | 3.24±0.14 | |
| ? | Western medicine processed |
5 | 2.36±0.36 | 2.60±0.13 | 3.16±0.13 | 3.47±0.23 |
1.2 impacts of various dose group Chinese medicine on PD rat model AIM total points
Medication is marked for the 8th, 15,22,29 days, find low dose group medication to the 15,22,29 days, AIM total points is (9.73 ± 0.52), (9.82 ± 0.37) and (10.18 ± 0.32) minute, compared with Western medicine group (10.58 ± 0.40), (11.51 ± 0.17) minute and (11.58 ± 0.24) minute obviously reduce (<i TranNum="390">t</i>=2.88,<i TranNum="391">t</i>=9.25,<i TranNum="392">t</i>=7.77, all<i TranNum="393">p</i><0.05).And middle dosage group AIM total points is respectively (8.82 ± 0.36), (8.71 ± 0.47), (8.13 ± 0.37) and (7.89 ± 0.57) minute all lower than small dose group total points, difference have statistical significance (<i TranNum="394">t</i>=3.32,<i TranNum="395">t</i>=3.19,<i TranNum="396">t</i>=7.56,<i TranNum="397">t</i>=7.85, all<i TranNum="398">p</i><0.05); In the 8th, 15,22 days, heavy dose of group AIM total points was respectively (8.20 ± 0.27), (7.80 ± 0.34), (7.55 ± 0.38) minute, in dosage group low, difference have statistical significance (<i TranNum="399">t</i>=3.12,<i TranNum="400">t</i>=3.44,<i TranNum="401">t</i>=2.57, all<i TranNum="402">p</i><0.05), and the 29th day heavy dose of group (6.71 ± 1.13) minute and the comparison of middle dosage group, difference not statistically significant (see figure 1).
the impact of various dose Chinese medicine composition on PD rat model agent peak number of revolutions
In the 8th, 15,22,29 days, carry out agent peak number of revolutions and detect, find that low dose group scoring (123.6 ± 11.91), (132 ± 10.07), (151 ± 15.73) and (155.8 ± 7.40) are inferior, little with Western medicine group difference; And middle dosage group and small dose group comparison, middle dosage group agent peak number of revolutions is respectively (87.4 ± 15.60), (83.0 ± 21.76), (88 ± 10.20) and (73 ± 15.18), all lower than small dose group, difference have statistical significance (<i TranNum="406">t</i>=4.13,<i TranNum="407">t</i>=4.57,<i TranNum="408">t</i>=7.51,<i TranNum="409">t</i>=10.96, all<i TranNum="410">p</i><0.05); Heavy dose of group and the comparison of middle dosage group, within the 22nd, 29 days, the inferior middle dosage group of heavy dose of group agent peak number of revolutions (51.2 ± 6.76) and (53.8 ± 7.79) is low, difference have statistical significance (<i TranNum="411">t</i>=6.73,<i TranNum="412">t</i>=2.52, all<i TranNum="413">p</i><0.05) (see figure 2).
the impact of various dose Chinese medicine composition on PD motor complication Striatum of Rats signal protein
2.1 impacts of Chinese medicine composition various dose on PD rat model Striatum GRK6
Showed by immune group result GRK6 expresses on cell membrane.Each group is not damaged the comparison of side average, difference not statistically significant (<i TranNum="419">f</i>=0.17,<i TranNum="420">p</i>>0.05), and each group damage side average significant difference (<i TranNum="421">f</i>=4.48,<i TranNum="422">p</i><0.05).PD Damage of Rats side GRK6 expression is (4.53 ± 0.85) * 10<sup TranNum="423">3</sup>, (6.10 ± 0.55) * 10 of compared with normal rat<sup TranNum="424">3</sup>obviously reduce (<i TranNum="425">t</i>=9.99,<i TranNum="426">p</i><0.01); After life-time service levodopa treatment, GRK6 expresses and is further reduced to (3.52 ± 0.71) * 10<sup TranNum="427">3</sup>, with the comparison of PD rat, difference have statistical significance (<i TranNum="428">t</i>=2.99,<i TranNum="429">p</i><0.05); And add the rat with Chinese herb on the prevention, and striatal damage side GRK6 expresses and the comparison of PD rat, all without further reducing, and with the rat comparison of using levodopa, small dose group (4.17 ± 1.20) * 10<sup TranNum="430">3</sup>with Western medicine group zero difference, the expression of middle dosage group, heavy dose of group damage side GRK6 is respectively (4.21 ± 0.95) * 10<sup TranNum="431">3</sup>, (4.78 ± 1.24) * 10<sup TranNum="432">3</sup>, with the comparison of Western medicine group, GRK6 expression obviously more (<i TranNum="433">t</i>=3.79,<i TranNum="434">t</i>=4.84, all<i TranNum="435">p</i><0.05) (see figure 3).
Western result and SABC are basically identical.With regard to every rat, testing result is with damage side/do not damage the ratio value representation of side, and β-actin is as internal reference.With (100.78 ± 5.57) % comparison of sham operated rats, PD rat GRK6 expression is reduced to (81.32 ± 5.94) %, significant difference (<i TranNum="437">t</i>=7.37,<i TranNum="438">p</i><0.01); Levodopa long-term treatment has further reduced GRK6 expression to (72.66 ± 3.43) %, difference have statistical significance (<i TranNum="439">t</i>=3.11,<i TranNum="440">p</i><0.05); And add rat striatum GRK6 expression and the comparison of PD rat with Chinese herb on the prevention, difference not statistically significant.With the rat comparison of life-time service levodopa, % is obviously higher for middle dosage group striatum GRK6 expression (83.78 ± 4.50), difference have statistical significance (<i TranNum="441">t</i>=7.26,<i TranNum="442">p</i><0.01), small dose group (79.02 ± 3.15) % and heavy dose of group of (80.46 ± 4.74) % and its comparison, the remarkable (see figure 4) of difference.
the impact of Chinese medicine various dose on PD motor complication rat model Striatum β-arrestin1
SABC shows that β-arrestin1 is expressed in cell membrane, each group damage side average significant difference (F=5.76, P < 0.05).The positive cell index of PD rat β-arrestin1 albumen is (3.20 ± 0.75) * 10<sup TranNum="446">4</sup>(4.50 ± 0.63) * 10 lower than rats in sham-operated group<sup TranNum="447">4</sup>, but difference not statistically significant.After levodopa long-term treatment, β-arrestin1 expresses further and reduces, and positive cell index is (2.50 ± 0.49) * 10<sup TranNum="448">4</sup>, with the comparison of PD rat, difference has statistical significance (t=3.90, P<0.05).Add with rat β-arrestin1 positive cell index of Chinese medicine and do not occur further decline, particularly middle dosage group rat β-arrestin1 positive cell index is (3.67 ± 0.51) * 10<sup TranNum="449">4</sup>, than PD rat, increase (t=6.80, P<0.01).Large and small dosage group β-arrestin1 positive cell index is respectively (3.20 ± 0.68) * 10<sup TranNum="450">4</sup>(3.10 ± 0.59) * 10<sup TranNum="451">4</sup>between relatively, with PD group relatively, without significant difference (see figure 5).
Western result and SABC are basically identical.Every rat Western result is with damage side/do not damage the ratio value representation of side, and β-actin is as internal reference.PD rat β-arrestin1 expressing quantity is (76.41 ± 5.12) %, than rats in sham-operated group (100.86 ± 6.79) % obviously reduce (<i TranNum="453">t</i>=11.48,<i TranNum="454">p</i><0.01).Levodopa long-term treatment has further reduced β-arrestin1 expression, is (65.04 ± 6.68) %, with the comparison of PD group rat, difference have statistical significance (<i TranNum="455">t</i>=8.31,<i TranNum="456">p</i><0.01).Add with after Chinese herb on the prevention, small dose group β-arrestin1 expression is (69.34 ± 3.36) %, compared with PD rat group reduce (<i TranNum="457">t</i>=3.42,<i TranNum="458">p</i><0.05), present the trend similar to Western medicine group; And middle dosage group and heavy dose of group are respectively (73.42 ± 3.82) % and further decline does not appear in (72.36 ± 6.66) %.Meanwhile, middle dosage group and heavy dose of group striatum β-arrestin1 expression be apparently higher than the rat of life-time service levodopa, difference have statistical significance (<i TranNum="459">t</i>=3.11,<i TranNum="460">t</i>=3.70,<i TranNum="461">p</i><0.05).Between middle dosage group and heavy dose of group relatively, difference not statistically significant (see figure 6).
chinese medicine various dose is on PD motor complication rat model Striatum phosphorylation DARPP-32(Thr75) impact expressed
Each group damage side average significant difference of SABC demonstration (<i TranNum="465">f</i>=472.10,<i TranNum="466">p</i><0.01).Rats in sham-operated group phosphorylation DARPP-32(Thr75) expression is (7.01 ± 0.57) * 10<sup TranNum="467">6</sup>, PD group is increased to (11.50 ± 0.16) * 10<sup TranNum="468">6</sup>, difference have statistical significance (<i TranNum="469">t</i>=14.07,<i TranNum="470">p</i><0.01).After levodopa long-term treatment, phosphorylation DARPP-32(Thr75) be expressed as (3.85 ± 0.30) * 10<sup TranNum="471">6</sup>, than PD group, obviously reduce, difference have statistical significance (<i TranNum="472">t</i>=38.99,<i TranNum="473">p</i><0.01).Add the rat with Chinese medicine, large, medium and small dosage group phosphorylation DARPP-32(Thr75) express and be respectively (12.34 ± 0.19) * 10<sup TranNum="474">6</sup>, (11.89 ± 0.47) * 10<sup TranNum="475">6</sup>(7.20 ± 0.27) * 10<sup TranNum="476">6</sup>, significantly reducing does not all appear in middle dosage group and heavy dose of group, and only small dose group reduces.Between heavy dose of group and middle dosage group, compare difference not statistically significant (see figure 7).
Western result and SABC are basically identical, rats in sham-operated group phosphorylation DARPP-32(THr75) gray value of expressing is (2.06 ± 0.24) * 10<sup TranNum="478">6</sup>, PD group rat is (3.04 ± 0.20) * 10<sup TranNum="479">6</sup>, two groups of comparing differences have statistical significance (<i TranNum="480">t</i>=28.95,<i TranNum="481">p</i><0.01).Adding with not playing preventive effect, phosphorylation DARPP-32(THr75 after low dose of Chinese medicine) expression is (1.85 ± 0.15) * 10<sup TranNum="482">6</sup>, compared with PD rat reduce (<i TranNum="483">t</i>=19.77,<i TranNum="484">p</i><0.01); The rat striatum phosphorylation DARPP-32(THr75 that adds dosage Chinese herb on the prevention in using) expression is (3.10 ± 0.15) * 10<sup TranNum="485">6</sup>, with the comparison of PD rat, difference not statistically significant (<i TranNum="486">p</i>>0.05).Heavy dose of group phosphorylation DARPP-32(THr75) expression is (3.73 ± 0.17) * 10<sup TranNum="487">6</sup>,, compared with PD rat slightly increase (t=38.57,<i TranNum="488">p</i><0.01), meanwhile, dosage group increasing expression in heavy dose of group ratio (<i TranNum="489">t</i>=21.78,<i TranNum="490">p</i><0.01) (see figure 8).
the impact that Chinese medicine various dose is expressed PD motor complication rat model Striatum phosphorylation ERK1/2
Each group damage side average significant difference of SABC demonstration (<i TranNum="494">f</i>=117.49,<i TranNum="495">p</i><0.01).PD rat phosphorylation ERK1/2 expression is (4.30 ± 0.23) * 10<sup TranNum="496">4</sup>, lower than (5.20 ± 0.34) * 10 of rats in sham-operated group<sup TranNum="497">4</sup>, difference have statistical significance (<i TranNum="498">t</i>=15.32,<i TranNum="499">p</i><0.01).After levodopa long-term treatment, phosphorylation ERK1/2 expresses and is increased to (8.08 ± 0.37) * 10<sup TranNum="500">4</sup>, with PD group relatively, difference have statistical significance (<i TranNum="501">t</i>=34.13,<i TranNum="502">p</i><0.01).Add the rat with Chinese medicine, small dose group phosphorylation ERK1/2 is expressed as (6.59 ± 0.36) * 10<sup TranNum="503">4</sup>, in rising trend, middle dosage group and heavy dose of group expression are (4.49 ± 0.34) * 10<sup TranNum="504">4</sup>(4.26 ± 0.25) * 10<sup TranNum="505">4</sup>, all do not occur significantly rising.Between heavy dose of group and middle dosage group, relatively, difference is not obvious.(see figure 9).
Western result and SABC are basically identical, and the gray value that PD rat phosphorylation ERK1/2 expresses is (2.83 ± 0.17) * 10<sup TranNum="507">6</sup>, than (3.50 ± 0.12) * 10 of rats in sham-operated group<sup TranNum="508">6</sup>reduce (<i TranNum="509">t</i>=20.77,<i TranNum="510">p</i><0.01); Add with the gray value that the rat striatum phosphorylation ERK1/2 of large, medium and small dosage Chinese herb on the prevention expresses and be respectively (3.23 ± 0.19) * 10<sup TranNum="511">6</sup>, (3.15 ± 0.16) * 10<sup TranNum="512">6</sup>(4.40 ± 0.16) * 10<sup TranNum="513">6</sup>, more all have rising in various degree with PD rat, difference all have statistical significance (<i TranNum="514">t</i>=13.81,<i TranNum="515">t</i>=3.41,<i TranNum="516">t</i>=45.12,<i TranNum="517">p</i><0.01).Wherein, middle dosage group phosphorylation ERK1/2 expression rising amplitude is minimum, the maximum (see figure 10) of small dose group rising amplitude.
In a word, middle dosage Chinese medicine composition has reversed the carrying out property rising of each component of PD rat AIM scoring, reduced PD rat agent peak number of revolutions, by increasing GRK6, β-arrestin1 expressing quantity, reverse phosphorylation DARPP-32(Thr75) reduction of expression and phosphorylation ERK1/2 express significantly and raise, the function of having improved signal transducers abnormal in LID born of the same parents, has reduced the generation of PD motor complication, is preventing PD and is delaying to have great using value aspect disease progression.
three, conclusion
Chinese medicine composition of the present invention, its compatibility meets Chinese medicine " monarch " principle, and flavour of a drug number is less, have curative effect high, have no side effect, the advantage such as price is low, adopt benefiting QI for activating blood circulation method, nourishing YIN for attracting YANG method, suppressing the hyperactive liver to relieve the wind syndrome method, rubs the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., the rules such as activating blood and removing stasis Method and dredging collateral relieve dizziness, high fever, infantile convulsions, epilepsy, etc., from cause of disease, start with at all, suit the remedy to the case, to reach preventive effect; Preparation method is simple, and cost is low, environmentally friendly, is suitable for long-term taking, is a kind of Chinese medicine composition that prevents safely and effectively parkinson disease and parkinson disease motor complication, has a good application prospect.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and supplement and also should be considered as protection scope of the present invention.
Claims (9)
1. a Chinese medicine prevents the application in Parkinsonian disease medicament in preparation, it is characterized in that, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 5-10 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part, Rhizoma Arisaematis 2-10 part.
2. application according to claim 1, it is characterized in that, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 6-8 part, Radix Astragali 6-8 part, Radix Rehmanniae Preparata 6-8 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-8 part, Ramulus Uncariae Cum Uncis 6-8 part, Bombyx Batryticatus 4-6 part, Rhizoma Arisaematis 4-6 part.
3. application according to claim 1, is characterized in that, described medicine is made by the crude drug of following weight portion: 8 parts, Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, 5 parts of Rhizoma Arisaematiss.
4. according to the arbitrary described application of claim 1-3, it is characterized in that the application of described medicine in the disease medicament of preparation prevention parkinson disease motor complication.
5. one kind is prevented Parkinsonian Chinese medicine, it is characterized in that, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 5-10 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part, Rhizoma Arisaematis 2-10 part.
6. medicine according to claim 5, it is characterized in that, described medicine is made by the crude drug of following weight portion: Rhizoma Gastrodiae 6-8 part, Radix Astragali 6-8 part, Radix Rehmanniae Preparata 6-8 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-8 part, Ramulus Uncariae Cum Uncis 6-8 part, Bombyx Batryticatus 4-6 part, Rhizoma Arisaematis 4-6 part.
7. medicine according to claim 5, is characterized in that, described medicine is made by the crude drug of following weight portion: 8 parts, Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, 5 parts of Rhizoma Arisaematiss.
8. according to the arbitrary described medicine of claim 5-7, it is characterized in that the application of described medicine in the disease medicament of preparation prevention parkinson disease motor complication.
9. according to the arbitrary described medicine of claim 5-7, it is characterized in that, the dosage form of described medicine is tablet, capsule, granule, mixture or syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210063022.3A CN102600374B (en) | 2012-03-12 | 2012-03-12 | Medicine for preventing parkinsonism and application of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210063022.3A CN102600374B (en) | 2012-03-12 | 2012-03-12 | Medicine for preventing parkinsonism and application of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102600374A CN102600374A (en) | 2012-07-25 |
| CN102600374B true CN102600374B (en) | 2014-01-22 |
Family
ID=46518393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210063022.3A Expired - Fee Related CN102600374B (en) | 2012-03-12 | 2012-03-12 | Medicine for preventing parkinsonism and application of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600374B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230485B (en) * | 2013-04-23 | 2014-12-10 | 彭连志 | Medicine for treating Parkinson's disease and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (en) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | Traditional Chinese medicine combination for treating parkinsonism and preparation method thereof |
-
2012
- 2012-03-12 CN CN201210063022.3A patent/CN102600374B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (en) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | Traditional Chinese medicine combination for treating parkinsonism and preparation method thereof |
Non-Patent Citations (10)
| Title |
|---|
| 严兴亚等.帕金森病中医药治疗研究进展.《现代中西医结合杂志》.2008,第17卷(第15期),第2407-2409页. |
| 中医药治疗帕金森病的思路与方法;张秋娟等;《中西医结合学报》;20040131;第2卷(第1期);第75-77页 * |
| 中西药合用对异动症大鼠行为学和氧化应激的影响;王洁等;《河北中医》;20090131;第31卷(第1期);第123-124页 * |
| 周小琳.镇颤舒胶囊合美多巴治疗帕金森病42例临床研究.《山西中医》.2004,第20卷(第1期),第23-24页. |
| 天麻对帕金森病大鼠神经元保护及机制的研究;徐瑰翎;《中国优秀硕士学位论文全文数据库》;20080215(第2期);第78页 * |
| 帕金森病中医药治疗研究进展;严兴亚等;《现代中西医结合杂志》;20080531;第17卷(第15期);第2407-2409页 * |
| 张秋娟等.中医药治疗帕金森病的思路与方法.《中西医结合学报》.2004,第2卷(第1期),第75-77页. |
| 徐瑰翎.天麻对帕金森病大鼠神经元保护及机制的研究.《中国优秀硕士学位论文全文数据库》.2008,(第2期),第78页. |
| 王洁等.中西药合用对异动症大鼠行为学和氧化应激的影响.《河北中医》.2009,第31卷(第1期),第123-124页. |
| 镇颤舒胶囊合美多巴治疗帕金森病42例临床研究;周小琳;《山西中医》;20040229;第20卷(第1期);第23-24页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102600374A (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Reflections on treatment of COVID-19 with traditional Chinese medicine | |
| US20060188586A1 (en) | Compositions and methods for enhancing therapeutic effects | |
| CN101062080B (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| EP3653219A1 (en) | Composition for treating fatty liver | |
| Sun et al. | Research progress of traditional Chinese medicine compound" Xiaochaihu Decoction" in the treatment of depression | |
| Meng et al. | From Xiaoke to diabetes mellitus: a review of the research progress in traditional Chinese medicine for diabetes mellitus treatment | |
| CN102600370B (en) | Application of Chinese medicinal composition in preparing medicament for preventing and treating Parkinsonism | |
| CN102600373B (en) | Traditional Chinese medicine composition for relieving parkinsonism motion complications | |
| CN103623222A (en) | Food, health-care product or medicinal composition with liver-protecting effect | |
| CN102526512B (en) | Traditional Chinese medicine for treating motor complications of Parkinson's diseases and application thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN102600372B (en) | Chinese medicinal composition for preventing Parkinsonism | |
| CN102600374B (en) | Medicine for preventing parkinsonism and application of medicine | |
| CN111407853A (en) | Traditional Chinese medicine composition for preventing and treating Parkinson's disease and preparation method thereof | |
| CN110876772A (en) | Preparation method and application of traditional Chinese medicine preparation with liver protection function | |
| Efferth et al. | Tonic herbs and herbal mixtures in Chinese medicine | |
| CN102600375B (en) | Medicine for treating parkinsonism motion complications and application of medicine | |
| CN102600371B (en) | Traditional Chinese medicine composition for preventing parkinsonism and application of traditional Chinese medicine composition | |
| CN102579847B (en) | Application of Chinese medicinal composition in preparing medicament for treating motion complications of Parkinson's disease | |
| CN102908596B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN103977154A (en) | Pharmaceutical composition for protecting liver | |
| CN101264208A (en) | Medicinal composition for treating stomach and intestine dysfunction and preparation thereof | |
| Lim et al. | The Natural Products Targeting on Allergic Rhinitis: From Traditional Medicine to Modern Drug Discovery. Antioxidants 2021, 10, 1524 | |
| Li et al. | Traditional Chinese medicine prescriptions and herbs for the treatment of hypothyroidism: a narrative review | |
| US20020058073A1 (en) | Compositions and methods for treating neck and shoulder discomfort |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20150312 |
|
| EXPY | Termination of patent right or utility model |